Products
Services
Applications
Resources Get started
Resource Centre
Back

Nanopore targeted sequencing for rapid gene mutations detection in acute myeloid leukemia

Publication

Date: 9th December 2019 | Source: Genes

Authors: Cosimo Cumbo,Crescenzio Francesco Minervini, Paola Orsini, Luisa Anelli, Antonella Zagaria, Angela Minervini, Nicoletta Coccaro, Luciana Impera, Giuseppina Tota, Elisa Parciante, Maria Rosa Conserva, Orietta Spinelli, Alessandro Rambald.

Acute myeloid leukemia (AML) clinical settings cannot do without molecular testing to confirm or rule out predictive biomarkers for prognostic stratification, in order to initiate or withhold targeted therapy. Next generation sequencing offers the advantage of the simultaneous investigation of numerous genes, but these methods remain expensive and time consuming.

In this context, we present a nanopore-based assay for rapid (24 h) sequencing of six genes (NPM1FLT3CEBPATP53IDH1 and IDH2) that are recurrently mutated in AML.

The study included 22 AML patients at diagnosis; all data were compared with the results of S5 sequencing, and discordant variants were validated by Sanger sequencing. Nanopore approach showed substantial advantages in terms of speed and low cost. Furthermore, the ability to generate long reads allows a more accurate detection of longer FLT3 internal tandem duplications and phasing double CEBPA mutations.

In conclusion, we propose a cheap, rapid workflow that can potentially enable all basic molecular biology laboratories to perform detailed targeted gene sequencing analysis in AML patients, in order to define their prognosis and the appropriate treatment.

Read the full text

Recommended for you

Open a chat to talk to our sales team
Subscribe

Subscribe

FAQs

FAQs

Search